News & Updates
Filter by Specialty:
Show Multimedia Only

NATALEE update: Ribociclib + NSAI well tolerated
12 Jul 2024
byElvira Manzano
Latest findings from the ongoing phase III NATALEE trial have shown that 3-year treatment with adjuvant ribociclib, in combination with a nonsteroidal aromatase inhibitor (NSAI), remained well tolerated in patients with HR+/HER2- early-stage breast cancer (EBC).